EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patients' and healthcare professionals' experiences with implementing the Rosa chatbot in mainstream genetic testing for hereditary breast and ovarian cancer

Elen Siglen iD, Hildegunn Høberg Vetti iD, Anita Lyssand iD, Tone Dahl-Michelsen iD, Cathrine Bjorvatn iD

Journal of Genetic Counseling · 2025

DOI: 10.1002/jgc4.70119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Genetic Counseling, 2025. Verfasst von Elen Siglen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Studies, VID Specialized University, Bergen, Norway. Hauptthemen laut MEDLINE: Genetic Testing, Ovarian Neoplasms, Breast Neoplasms, Health Personnel. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kreftforeningen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mainstream genetic testing (MGT) refers to genetic testing conducted at the time of a cancer diagnosis without undergoing comprehensive genetic counseling. MGT has been the standard of care for patients with breast or ovarian cancer in Norway for several years. The aim of this study is to explore how newly diagnosed patients with breast or ovarian cancer and healthcare professionals' (HCPs), experience the use of the Rosa chatbot in mainstream genetic testing (MGT) and explore potential barriers to the implementation of chatbots in MGT. We conducted a qualitative study using semi‐structured interview guides with selected patients and HCPs. The interviews were done either: in‐person, over the digital platform Teams, or over the telephone, depending on the participants' wishes. We chose the Stepwise‐Deductive Inductive approach for analyzing the transcripts. Both patients and HCPs viewed the Rosa chatbot positively, describing it as user‐friendly, useful, accessible, safe, professional, and trustworthy. They reported that the volume and complexity of information during MGT could be overwhelming and viewed the chatbot as a trustworthy resource for patients to revisit at their own pace, supporting informed decision‐making after a positive genetic test result. However, concerns were raised about potential misunderstandings, the impersonal nature of digital communication, and the risk of reduced patient–provider interaction, which together were perceived as an emotional barrier to integrating chatbots into genetic counseling practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingOvarian NeoplasmsBreast NeoplasmsHealth PersonnelHumansFemaleAdultMiddle AgedGenetic CounselingNorwayGenerative Artificial Intelligence

Stichwörter der Autor:innen

BRCA1BRCA2HBOCbreast cancerchatbotdigital tooldigitizing healthcaregenetic counselingimplementation barriermainstream genetic testingovarian cancerpatient‐centered care

Autor:innen und Institutionen

  • Faculty of Health Studies, VID Specialized University, Bergen, Norway.
  • Western Norway Familial Cancer Center, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway.

ORCID-Profile: Elen Siglen, Hildegunn Høberg Vetti, Anita Lyssand, Tone Dahl-Michelsen, Cathrine Bjorvatn

Förderung

  • Kreftforeningen

Zitieren

APA

Siglen, E., Vetti, H. H., Lyssand, A., Dahl-Michelsen, T., & Bjorvatn, C. (2025). Patients' and healthcare professionals' experiences with implementing the Rosa chatbot in mainstream genetic testing for hereditary breast and ovarian cancer. Journal of Genetic Counseling. https://doi.org/10.1002/jgc4.70119

Vancouver

Siglen E, Vetti HH, Lyssand A, Dahl-Michelsen T, Bjorvatn C. Patients' and healthcare professionals' experiences with implementing the Rosa chatbot in mainstream genetic testing for hereditary breast and ovarian cancer. Journal of Genetic Counseling. 2025. doi:10.1002/jgc4.70119

BibTeX
@article{Siglen2025,
  author = {Siglen, Elen and Vetti, Hildegunn Høberg and Lyssand, Anita and Dahl-Michelsen, Tone and Bjorvatn, Cathrine},
  title = {Patients' and healthcare professionals' experiences with implementing the Rosa chatbot in mainstream genetic testing for hereditary breast and ovarian cancer},
  journal = {Journal of Genetic Counseling},
  year = {2025},
  doi = {10.1002/jgc4.70119}
}
Kostenlos starten →